Comparative Pharmacology
Head-to-head clinical analysis: MULTAQ versus SORINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MULTAQ versus SORINE.
MULTAQ vs SORINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dronedarone is a multichannel blocker that inhibits potassium currents (IKr, IKs, IK-ACh), sodium current (INa), and L-type calcium current (ICaL), and has antiadrenergic properties via noncompetitive blockade of beta-adrenergic receptors.
Selective beta-1 adrenergic receptor antagonist; decreases cardiac output, heart rate, and blood pressure.
400 mg orally twice daily with morning and evening meals.
5 mg orally once daily, increased after 4 weeks to 10 mg orally once daily if tolerated and needed.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) after oral administration, allowing for twice-daily dosing.
4-6 hours in healthy adults; prolonged to 12-18 hours in severe renal impairment (CrCl <30 mL/min).
Primarily fecal (84%) after biliary excretion; renal excretion accounts for <6% as unchanged drug and metabolites.
Renal (80% unchanged) and biliary (15% as metabolites); 5% fecal.
Category C
Category C
Antiarrhythmic
Antiarrhythmic